Medtronic Downgraded to $80 Price Target While Q4 Revenue Jumps 9.9% to $9.81B
MDT•Stifel Nicolaus cut Medtronic’s price target to $80 from $95 despite Q4 revenue of $9.81 billion (+9.9%) and full-year sales of $36.4 billion (+8.4%). Cardiac Ablation Solutions revenue jumped 78% globally, yet FY27 EPS guidance of $5.90–$6.00 trails the $6.05 consensus due to tariffs and MiniMed separation costs.
1. Analyst Downgrade
Rick Wise of Stifel Nicolaus lowered Medtronic’s price target from $95 to $80, implying just a 2.6% upside from the then-trading level of $77.95 despite recent strong financials.
2. Q4 and Full-Year Financial Performance
Medtronic reported its best top-line showing in a decade with Q4 revenue of $9.81 billion (+9.9%) and full-year sales of $36.4 billion (+8.4%), driving a 5.46% stock uplift post-announcement.
3. Cardiac Ablation Solutions Surge
The Cardiac Ablation Solutions business led growth, with revenue up 78% globally and 124% in the US, capturing eight additional U.S. market share points and nearing $2.0 billion in trailing revenue.
4. Fiscal 2027 Outlook
Management projects 6.75%–7.25% organic revenue growth next fiscal year, but EPS guidance of $5.90–$6.00 falls below the $6.05 analyst consensus due to tariff headwinds and MiniMed separation costs.
